[go: up one dir, main page]

MX2014012945A - Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX2014012945A
MX2014012945A MX2014012945A MX2014012945A MX2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A MX 2014012945 A MX2014012945 A MX 2014012945A
Authority
MX
Mexico
Prior art keywords
aminopyrimidine derivatives
lrrk2
pyrazole
modulators
lrrk2 modulators
Prior art date
Application number
MX2014012945A
Other languages
English (en)
Other versions
MX363118B (es
Inventor
Huifen Chen
Charles Baker-Glenn
Mark Chambers
Bryan K Chan
Anthony Estrada
Daniel Jon Burdick
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014012945A publication Critical patent/MX2014012945A/es
Publication of MX363118B publication Critical patent/MX363118B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con compuestos de pirazol que son moduladores de LRRK2, con métodos para elaborar los compuestos, y con métodos para usar los compuestos para el tratamiento de enfermedades asociadas con el receptor LRRK2, tal como la enfermedad de Parkinson.
MX2014012945A 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). MX363118B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (2)

Publication Number Publication Date
MX2014012945A true MX2014012945A (es) 2015-02-10
MX363118B MX363118B (es) 2019-03-11

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012945A MX363118B (es) 2012-05-03 2013-04-30 Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (10)

Country Link
US (1) US9212173B2 (es)
EP (1) EP2844652B1 (es)
JP (1) JP6218808B2 (es)
KR (1) KR102091894B1 (es)
CN (2) CN104271569B (es)
BR (1) BR112014026952B1 (es)
CA (1) CA2870049C (es)
MX (1) MX363118B (es)
RU (1) RU2637947C2 (es)
WO (1) WO2013164321A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871375C (en) * 2012-05-03 2020-10-27 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
US9376345B2 (en) 2013-06-25 2016-06-28 Carboncure Technologies Inc. Methods for delivery of carbon dioxide to a flowable concrete mix
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
MX2016007898A (es) 2013-12-20 2016-10-07 Signal Pharm Llc Compuestos diaminopirimidilo sustituidos, las composiciones de estos y los metodos de tratamiento con estos.
JP6422986B2 (ja) 2014-01-29 2018-11-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
CA2937430A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
CA2955882A1 (en) * 2014-07-24 2016-01-28 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
AU2016369584A1 (en) 2015-12-16 2018-07-19 Southern Research Institute Pyrrolopyrimidine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
PE20240221A1 (es) * 2016-06-16 2024-02-16 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
EP4265597A3 (en) 2017-06-30 2023-11-22 Amgen Inc. Synthesis of omecamtiv mecarbil
MY209751A (en) 2017-11-21 2025-07-31 Denali Therapeutics Inc Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
MX2020006641A (es) 2017-12-20 2021-01-08 Denali Therapeutics Inc Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
JPWO2019159248A1 (ja) 2018-02-14 2021-01-28 大阪有機化学工業株式会社 耐熱性且つ易剥離性の硬化樹脂膜を形成するための硬化性樹脂組成物及びその製造方法
WO2019160037A1 (ja) * 2018-02-14 2019-08-22 国立大学法人 東京大学 酸ハロゲン化物による化合物の製造方法
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
TWI850262B (zh) * 2018-09-25 2024-08-01 美商卡都瑞恩醫藥公司 胺基嘧啶化合物
CN111718332B (zh) * 2019-03-19 2021-08-17 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
US12421169B2 (en) 2019-04-26 2025-09-23 Carboncure Technologies Inc. Carbonation of concrete aggregates
WO2020247298A2 (en) * 2019-06-06 2020-12-10 Merck Sharp & Dohme Corp. 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
AU2021363536A1 (en) 2020-10-20 2023-02-23 F. Hoffmann-La Roche Ag Combination therapy of PD-1 axis binding antagonists and LRRK2 inhitibors
WO2022093881A1 (en) 2020-10-29 2022-05-05 Merck Sharp & Dohme Corp. N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
KR20250097874A (ko) 2022-11-03 2025-06-30 데날리 테라퓨틱스 인크. 피리미딘 트리아졸 화합물의 고체 및 공결정형
CN120659780A (zh) 2022-11-22 2025-09-16 戴纳立制药公司 嘧啶氨基吡唑化合物的制备方法和中间体
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用
CN119968373A (zh) * 2023-09-07 2025-05-09 上海翊石医药科技有限公司 一种芳杂环类化合物及其制备方法
WO2026002197A1 (zh) * 2024-06-28 2026-01-02 成都康弘药业集团股份有限公司 一种治疗或预防lrrk2介导的疾病的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002022607A1 (en) * 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
JP2011513483A (ja) * 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
EP2440548A1 (en) * 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
MX2012014158A (es) * 2010-06-04 2013-02-07 Hoffmann La Roche Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2).
KR101837223B1 (ko) * 2010-09-01 2018-03-09 질레드 코네티컷 인코포레이티드 피리디논/피라지논, 그의 제조 방법 및 사용 방법
PT3124483T (pt) * 2010-11-10 2019-10-02 Genentech Inc Derivados de pirazol aminopirimidina como moduladores de lrrk2
RU2014109897A (ru) * 2011-08-25 2015-09-27 Ф.Хоффманн-Ля Рош Аг Ингибиторы серин/треонин киназы рак1
TWI553004B (zh) * 2011-11-03 2016-10-11 建南德克公司 ８－氟基呔－１（２ｈ）－酮化合物
MY191936A (en) * 2012-03-01 2022-07-19 Genentech Inc Serine/threonine kinase inhibitors
KR102281288B1 (ko) * 2012-09-26 2021-07-26 에프. 호프만-라 로슈 아게 환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
PE20161063A1 (es) * 2013-05-01 2016-10-22 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos

Also Published As

Publication number Publication date
BR112014026952A2 (pt) 2017-06-27
JP6218808B2 (ja) 2017-10-25
MX363118B (es) 2019-03-11
EP2844652A1 (en) 2015-03-11
CN104271569A (zh) 2015-01-07
CN104271569B (zh) 2016-08-24
WO2013164321A1 (en) 2013-11-07
KR102091894B1 (ko) 2020-03-20
HK1200820A1 (zh) 2015-08-14
KR20150016532A (ko) 2015-02-12
US20150051238A1 (en) 2015-02-19
US9212173B2 (en) 2015-12-15
JP2015515966A (ja) 2015-06-04
CN106220615A (zh) 2016-12-14
EP2844652B1 (en) 2019-03-13
CA2870049A1 (en) 2013-11-07
BR112014026952B1 (pt) 2022-03-15
RU2014147381A (ru) 2016-06-27
CA2870049C (en) 2020-12-29
BR112014026952A8 (pt) 2021-06-15
RU2637947C2 (ru) 2017-12-08

Similar Documents

Publication Publication Date Title
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
PH12013500880A1 (en) Pyrazole aminopyrimidine derivatives as lrrk2 modulators
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PH12012502373A1 (en) Aminopyrimidine derivatives as lrrk2 modulators
NZ737399A (en) Ccr2 modulators
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
MX2015000129A (es) Derivados de pirimidin pirazolilo.
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
EP4450130A3 (en) Formulations of enzalutamide
PL2785711T3 (pl) Pochodne 2-(fenylo lub piryd-3-ylo)aminopirymidyny jako modulatory kinazy lrrk2 do leczenia choroby parkinsona
HK1213888A1 (zh) 治療化合物和組合物以及其作為pkm2調節劑的用途
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
MX2014010537A (es) Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
MX371343B (es) Moduladores del receptor x hepatico (lxr).